Embodiments of the disclosure concern systems, methods, and/or compositions for cultivation of mammalian viruses, including at least human noroviruses and sapoviruses within the Caliciviridae family of viruses. The ex vivo culture systems include intestinal enteroids in combination with bile or a functionally active fraction or component thereof. In specific embodiments, the culture system is utilized to test inactivation compounds for therapeutic or environmental efficacy and to test contaminated comestibles and/or environmental entities for determination of the presence of infectious virus. Furthermore, antiviral compositions may be tested using systems of the disclosure, including drugs, small molecule inhibitors, and biologics such as neutralizing monoclonal antibodies.

Fusion proteins comprising a carrier protein and a Human Rhinovirus (HRV) peptide, and immunogenic compositions containing such fusion proteins.

Fusion proteins comprising a carrier protein and a Human Rhinovirus (HRV) peptide, and immunogenic compositions containing such fusion proteins.

The present invention relates to synthetic, consensus foot-and-mouth disease virus serotype O (FMDV-O) immunogenic proteins and nucleic acid molecule encoding such proteins and to methods for inducing immune responses against FMVD-O.

Fusion proteins comprising a carrier protein and a Human Rhinovirus (HRV) peptide, and immunogenic compositions containing such fusion proteins.

Fusion proteins comprising a carrier protein and a Human Rhinovirus (HRV) peptide, and immunogenic compositions containing such fusion proteins.

The disclosure provides immunogenic compositions comprising human picornavirus peptides derived from structural proteins of the virus, constructs comprising the peptides, the peptides themselves and their use in the prevention of picornavirus infection and disease. Particular peptides from VP4 and VP1 are disclosed.

The disclosure provides immunogenic compositions comprising human picornavirus peptides derived from structural proteins of the virus, constructs comprising the peptides, the peptides themselves and their use in the prevention of picornavirus infection and disease. Particular peptides from VP4 and VP1 are disclosed.

Disclosed in the present invention are an RNA replicon for improving gene expression, and a use thereof. The RNA replicon comprises: 5 and 3 untranslated regions; a non-structural protein gene coding region, a subgenomic promoter and a target gene coding region. In the present invention, a PCR site-directed mutagenesis technique is used to introduce the non-structural protein region mutant replicable RNA, which is transfected into mammalian eukaryotic cells by means of Lipofectamine 2000 or nanoparticles, so as to significantly enhance the expression of cytokines and chemokines including GM-CSF, IFN-, IL-2, IL-12, IL-15 mediated by downstream subgenomic promoters, and can be applied to treatment of tumors, infectious diseases, autoimmune diseases, hereditary diseases or cardiovascular diseases.